Mitosis-targeted anti-cancer therapies : where they stand
The strategy of clinically targeting cancerous cells at their most vulnerable state during mitosis has instigated numerous studies into the mitotic cell death (MCD) pathway. As the hallmark of cancer revolves around cell-cycle deregulation, it is not surprising that antimitotic therapies are effecti...
| Main Authors: | , , |
|---|---|
| Other Authors: | |
| Format: | Journal Article |
| Published: |
2013
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10356/99097 http://hdl.handle.net/10220/12878 |